Although the American College of Obstetricians and Gynecologists and the US Preventive Services Task Force recommend screening for depression in the general adult population, including pregnant and postpartum women, evidence for such screening in the perinatal setting is limited.
Variations in manager reactions and support for those with depression are as important as gross domestic product for absenteeism and presenteeism due to depression.
The prevalence of depression is 4.4% among fathers of children age 15 months or younger attending a well-child care clinic visit.
Results showed that discontinuation of any SNRI was associated with withdrawal symptoms, with the highest prevalence linked to venlafaxine and desvenlafaxine.
The use of certain antidepressants may put patients at increased risk for extrapyramidal symptoms.
When assessing risk for postpartum episodes, clinicians should inquire about family history of psychiatric disorders broadly and not limit discussion to postpartum psychiatric disorders or psychiatric disorders in female relatives.
Treatment with brexpiprazole as adjunctive antidepressant therapy was safe and effective in patients with major depressive disorder.
The average MADRS-10 scores decreased from baseline, and this decrease was maintained at the end of the study.
These data indicate a potential association between prenatal SSRI exposure and the development of the fetal amygdala-insula circuit, possibly via anomalous serotonin signaling.
If approved, esketamine has the potential to be the first treatment for patients with major depressive disorder at imminent risk for suicide.
ALKS 5461 consists of a fixed-dose combination of buprenorphine and samidorphan.
Major depressive disorder with psychotic features had comparative long-term outcomes with schizophrenia, schizoaffective disorder, and bipolar disorder.
Children of first-cousin consanguineous parents have increased odds of mental health issues and needing antidepressant medications.
Investigators assessed the prevalence and risk factors associated with symptoms of anxiety and depression in adolescents with HIV and those without infection but affected by HIV.
Selective serotonin reuptake inhibitors and other antidepressants, such as tricyclic antidepressants, are associated with increased adverse outcomes in patients aged 20 to 64 years diagnosed with depression.
Ceasing regular exercise increases depressive symptoms, particularly in women.
Individuals with chronic pain and comorbid depression may experience higher levels of stigma related to their conditions compared with patients with chronic pain alone.
Findings from a cohort study suggest that ECT is not associated with increased risk for dementia, even in the elderly.
Many non-pregnant women of childbearing age are suffering from untreated depression.
Practice guidelines have been updated to assist primary care physicians in the screening and treatment of adolescent depression.
Bipolar disorder (31.9%), depression (19.8%), schizophrenia (14.2%), and anxiety disorders (9.1%) were the most common mental health issues reported. Approximately 13% of evacuees with a mental health concern reported a history of post-traumatic stress disorder.
These results indicated a persistence of depressive and antisocial symptoms and related behavioral patterns far beyond what has been demonstrated in prior research.
Alcohol use disorder and depression were both associated with higher disengagement from antiretroviral therapy for patients with HIV.
The issue of whether and how prenatal SSRI exposure affects offspring has remained murky.
Fair to poor concordance was seen between dermatologist assessment and patient self-reporting.
Variability in definitions of "anxious depression" in research impedes the ability to make clear comparisons.
These findings show that electroconvulsive therapy is a medically appropriate choice for elderly adults with depression and is likely to produce sustained improvement.
Single-question self-assessment is not a sufficient marker of identifying depression in people with IBD.
The relationship between selective serotonin-reuptake inhibitor use and outcomes after ischemic stroke was examined.
Treatment with biologic agents in psoriasis may reduce risk for depressive symptoms.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- FDA Approves Powerful New Opioid Despite Criticisms
- Heart Rate Variability Predicts Treatment Response in Anxious Depression
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Psychotropic Medication May Reduce Symptoms and Improve Functioning in PTSD
- Social Decline a Predictor of Conversion Outcome in High-Risk Individuals
- Buprenorphine/Samidorphan Helpful in Refractory Depression